Increasing cancer incidence rates in younger and older adults worldwide
1. In this surveillance study, the incidence rates of several cancers increased among both younger and older adults in many ...
Tag: cancer
Punjab launches AI screening program this week
1. Punjab launched India’s first large-scale AI screening program for cancer and eye disease. 2. The initiative aims to perform ...
![2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/Untitled-design-350x250.png)
2MM: AI Roundup –Lilly launches TuneLab AI drug discovery, smart wound healing bandage, and Punjab cancer screening [September 25th, 2025]
Lilly unveils TuneLab AI platform for biotechs On September 9, 2025, Eli Lilly officially unveiled TuneLab, a federated AI platform ...
2MM: AI Roundup –Dermatology accuracy, faster drug discovery, heart disease detection, and global medical training [September 11th, 2025]
Google’s AI matches dermatologists in melanoma diagnosis England’s health service is piloting an artificial intelligence tool called Deep Ensemble for ...
Royalty financing deepens exposure to small cell lung cancer revenues
1. Royalty Pharma struck a deal worth up to 950 million dollars to buy into Amgen’s DLL3 directed bispecific for ...
The Scan by 2 Minute Medicine®: Fall boosters, mosquitoes, skin awareness, and Hollywood healing
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. FDA ...
Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths
Key Points: 1. Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. ...
Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer
1. Progression-free survival and overall survival were significantly greater in the combination therapy group compared to enzalutamide alone. 2. Anemia ...
mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial
1. In patients with metastatic pancreatic cancer, neither modified fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) or S-1, irinotecan and oxaliplatin ...
Randomized Phase III trial of Ramucirumab finds benefit for patients with refractory advanced gastric cancer
1. The addition of ramucirumab to irinotecan in patients with ramucirumab-refractory advanced or recurrent gastric or gastroesophageal cancer (AGC) did ...
